Ani Pharmaceuticals reported $2.36M in Interest Expense on Debt for its second fiscal quarter of 2020.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Interest Expense On Debt Change
Aerie Pharmaceuticals AERI:US $ 6M 0M
Ani Pharmaceuticals ANIP:US $ 2.36M 324K
Depomed DEPO:US $ 3.05M 1.45M
Eli Lilly And LLY:US $ 88.3M 4.2M
Endo International Ordinary Shares ENDP:US $ 135.83M 6.27M
Novartis NVS:US $ 209M 11M
Teva Pharmaceutical Industries TEVA:US $ 241M 0M